Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of September 2020, specifically dated September 8, 2020. The registrant is a foreign private issuer based in Lausanne, Switzerland, focused on research and clinical development.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a current report regarding a corporate transaction rather than a periodic financial statement.
Material Changes
On September 8, 2020, the Company entered into an Open Market Sales Agreement with Jefferies LLC. Key terms include:
- Offering Size: The Company may sell up to $80,000,000 of its common shares.
- Sales Method: Shares will be sold via "at the market" offerings as defined under Rule 415 of the Securities Act of 1933.
- Compensation: The Company will pay Jefferies LLC a commission of 3.0% of the gross sales price per share, plus certain incurred expenses.
- Flexibility: The Company has no obligation to sell any shares and may suspend the offering at any time.
Guidance, Outlook, and Risks
Use of Proceeds: The Company expects to use net proceeds from the sale of shares for research and clinical development of current and/or additional pipeline candidates, technology platforms, working capital, capital expenditures, and general corporate purposes.
Risks and Contingencies: The filing notes that representations and warranties in the agreement were made solely for the benefit of the contracting parties and may not reflect the actual state of affairs of the Company. Investors are cautioned that these contractual terms may differ from those applicable to investors and are subject to more recent developments.
Investor Verification Checklist
- Verify the actual volume and timing of share sales executed under the Open Market Sales Agreement in subsequent filings.
- Monitor the Company's cash position to assess the necessity of the $80,000,000 potential raise for ongoing clinical trials.
- Review the full text of the Open Market Sales Agreement (Exhibit 1.1) for specific covenants and termination rights not detailed in the summary.
- Check for any dilution impact on existing shareholders if the full $80,000,000 offering is executed.